-
公开(公告)号:US20110076274A1
公开(公告)日:2011-03-31
申请号:US12992312
申请日:2009-05-13
IPC分类号: A61K39/395 , G01N33/574 , C12Q1/68 , A61K39/39 , A61K31/704 , A61K31/675 , A61K31/337 , A61P35/00 , A61P35/04
CPC分类号: G01N33/57415 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , G01N2333/726 , G01N2500/04 , G01N2800/50 , G01N2800/52 , G01N2800/56
摘要: The present inventors demonstrate that the G-protein coupled receptor 55 (GPR55) is highly expressed in human aggressive breast cancer cells, and that the expression level may be correlated with the invasiveness and metastatic potential of these cells (for example metastasis to bone). In various aspects of the invention there are disclosed diagnostic tools or biomarkers that relate to the metastatic profile of breast cancer tumours. The invention also relates to pharmacological agents targeting this receptor for the purposes of inhibiting progression and spread of breast cancer.
摘要翻译: 本发明人证明,G蛋白偶联受体55(GPR55)在人侵袭性乳腺癌细胞中高度表达,并且表达水平可能与这些细胞(例如转移到骨)的侵袭和转移潜力相关。 在本发明的各个方面,公开了与乳腺癌肿瘤的转移概况相关的诊断工具或生物标志物。 本发明还涉及靶向该受体的药理学试剂,用于抑制乳腺癌的进展和扩散。